(JREE) JPMorgan s (Ireland) ICAV - - Ratings and Ratios
Exchange: SW • Country: Switzerland • Currency: EUR • Type: Etf • ISIN: IE00BF4G7183 • Europe Large-Cap Blend Equity
JREE: Equities, European, Stocks, Index, Tracker, Fund
The JPMorgan Europe Research Enhanced Index Equity UCITS ETF (ticker: JREE) is an exchange-traded fund domiciled in Ireland, designed for investors seeking exposure to large-cap equities across developed Europe. It tracks the Morningstar Developed Europe Target Market Exposure Net Return EUR index, offering a blend of growth and value stocks. This ETF is listed on the Swiss exchange (SW) and is structured as an ICAV (Irish Collective Asset-management Vehicle), which provides a tax-efficient vehicle for European investments.
With an AUM of approximately €47.183 billion, JREE is among the larger ETFs in its category, indicating significant investor interest and liquidity. The fund employs a research-enhanced indexing strategy, which combines the benefits of passive investing with active research to optimize returns. This approach aims to deliver performance that exceeds a traditional market-capitalization-weighted index while maintaining lower fees compared to actively managed funds.
The ETF has a total expense ratio (TER) of 0.15%, making it a cost-effective option for investors seeking European equity exposure. It distributes income annually and is denominated in euros. JREE is suitable for both institutional and retail investors looking for a diversified, large-cap equity allocation in their portfolios, with a focus on developed European markets.
Additional Sources for JREE ETF
JREE ETF Overview
Market Cap in USD | 49,556m |
Category | Europe Large-Cap Blend Equity |
IPO / Inception | 2020-06-30 |
JREE ETF Ratings
Growth 5y | 60.1% |
Fundamental | - |
Dividend | 0.0% |
Rel. Strength Industry | 4.72 |
Analysts | - |
Fair Price Momentum | 44.01 EUR |
Fair Price DCF | - |
JREE Dividends
No Dividends PaidJREE Growth Ratios
Growth Correlation 3m | 85% |
Growth Correlation 12m | 41.2% |
Growth Correlation 5y | 92.4% |
CAGR 5y | 9.41% |
CAGR/Max DD 5y | 0.30 |
Sharpe Ratio 12m | 0.91 |
Alpha | 3.96 |
Beta | 0.43 |
Volatility | 9.53% |
Current Volume | 1.2k |
Average Volume 20d | 1.7k |
As of February 22, 2025, the stock is trading at EUR 46.43 with a total of 1,197 shares traded.
Over the past week, the price has changed by +0.16%, over one month by +6.39%, over three months by +11.93% and over the past year by +14.88%.
Yes. Based on ValueRay Analyses, JPMorgan s (Ireland) ICAV - (SW:JREE) is currently (February 2025) a good stock to buy. It has a ValueRay Growth Rating of 60.05 and therefor a clear technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of JREE as of February 2025 is 44.01. This means that JREE is currently overvalued and has a potential downside of -5.21%.
JPMorgan s (Ireland) ICAV - has no consensus analysts rating.
According to ValueRays Forecast Model, JREE JPMorgan s (Ireland) ICAV - will be worth about 50.2 in February 2026. The stock is currently trading at 46.43. This means that the stock has a potential upside of +8.18%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 50.2 | 8.2% |